Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 8c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.21 --0%
EPS Growth %: -60.5%
Financial Fact:
Total operating expenses: 39.14M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -60.5%
Financial Fact:
Total operating expenses: 39.14M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.05, $0.08 worse than the analyst estimate of $0.13. Revenue for the quarter came in at $64.4 million versus the consensus estimate of $67 million.
GUIDANCE:
Vanda Pharmaceuticals sees Q3 2022 revenue of $240-280 million, versus the consensus of $265.1 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Starts Vanda Pharmaceuticals (VNDA) at Outperform
- Oppenheimer Starts Amneal Pharmaceuticals (AMRX) at Outperform
- Surf Air Mobility names Palantir veteran as president of SurfOS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
